Published online before print May 23, 2007, doi:10.1212/01.wnl.0000265517.66976.28)
J. J. Halperin, MD,
E. D. Shapiro, MD,
E. Logigian, MD,
A. L. Belman, MD,
L. Dotevall, MD,
G. P. Wormser, MD,
L. Krupp, MD,
G. Gronseth, MD and
C. T. Bever, Jr, MD
From the Department of Neurosciences (J.J.H.), Overlook Hospital, NYU School of Medicine, Summit, NJ; Departments of Pediatrics and Epidemiology and Public Health (E.D.S.), Yale University School of Medicine, New Haven, CT; Department of Neurology (E.L.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (A.L.B., L.K.), SUNY, Stony Brook, NY; Department of Infectious Diseases (L.D.), Sahlgrenska University Hospital, Gothenburg, Sweden; Division of Infectious Diseases (G.P.W.), Department of Medicine, New York Medical College, Valhalla; Department of Neurology (G.G.), University of Kansas Medical Center; and Research Service, VAMHCS, and the Department of Neurology (C.T.B.), University of Maryland School of Medicine.

View larger version (7K):
[in this window]
[in a new window]
|
Figure Relative efficacy of doxycycline vs parenteral treatment
Relative efficacy of doxycycline vs parenteral treatment (ratio of response rate to doxycycline to response rate to parenteral penicillin or ceftriaxone; RR of 1.0 indicating identical response rates with the agents being compared) in eight studies, and in aggregate. Responses in most studies were judged clinically; in study 6, CSF criteria were used as well. For summed data, RR is 0.986 (95% CIs 0.948 to 1.025). Additional analyses of doxycycline vs parenteral penicillin or ceftriaxone individually and of parenteral penicillin vs ceftriaxone similarly showed no significant differences. Key to studies: #127; #219; #315; #434; #514; #620; #733; #835.
|
|
Copyright © 2007 by AAN Enterprises, Inc.